Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines.
By: Michael Friedrich, Kathrin Reichert, Alena Woeste, Stephan Polack, Dorothea Fischer, Friederike Hoellen, Achim Rody, Frank Köster, Marc Thill

Department of Gynecology and Obstetrics, Helios Hospital Krefeld, Krefeld, Germany michael.friedrich@helios-kliniken.de.
2017-10-31; doi: 10.21873/anticanres.12340
Abstract

Background

Vitamin D is known for its anticancer potential. Prostaglandin E2 (PGE2) is a proliferative and inflammation-activating agent. The production of PGE2 is dependent on the activity of cyclooxygenase-2 (COX2). A link between vitamin D and PGE2 metabolism was shown recently.

Materials

In MDA-MB-231 and MCF-7 breast cancer cell lines, we investigated the influence of calcitriol and the COX2 inhibitor celecoxib on cell growth via the MTT test, as well as on the protein and mRNA expression of COX2 using western blot and quantitative real-time polymerase chain reaction (qRT-PCR).

Results

The proliferation of MCF-7 and MDA-MB-231 was inhibited by both calcitriol and the COX2 inhibitor celecoxib and even more strongly by their combination. Moreover, calcitriol inhibited COX2 protein expression in MDA-MB-231 cells, as well as COX2 mRNA expression in both cell lines.

Conclusion

The combination of calcitriol and celecoxib demonstrated a synergistic growth-inhibitory effect in breast cancer cell lines.



Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

PMID:29374758






Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements